Getting the
drop on cancer

When Sequenta launched ClonoSIGHT—the first DNA sequencing-based test for early detection of minimal residual disease (MRD), they created an entirely new category in cancer diagnostics. The challenge was to build a brand that would embody the simplicity of the test for patients, while reflecting an appropriate level of scientific expertise for physicians.